Mind Medicine (MindMed) Inc.
MNMDNASDAQHealthcare
$20.69
+$0.09(+0.44%)
Market Cap$1.6B
P/E Ratio—
52W High$21.08
52W Low$4.7
Mind Medicine (MindMed) Inc. (MNMD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MNMD · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 5, 2026EPS Actual
-$0.51
Est. -$0.48 · -6.3%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 5, 2026
After Market Close
▼ Miss EPS
MNMD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 7, 2026 | -$0.48 | — | — | — | — | — |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.48 | -$0.51 | -6.3% | — | — | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.52 | -$0.78 | -50.0% | — | — | — |
| ▼ Q3 FY2025 | Jul 31, 2025 | -$0.38 | -$0.50 | -31.6% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.36 | -$0.35 | +2.8% | — | — | — |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$0.33 | -$0.41 | -24.2% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.29 | -$0.27 | +6.9% | — | — | — |
| ▼ Q3 FY2024 | Aug 13, 2024 | -$0.30 | -$0.48 | -60.0% | — | — | — |
Q2 FY2026
May 7, 2026
EPS Actual
—
EPS Est.
-$0.48
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$0.51
EPS Est.
-$0.48
EPS Surpr.
-6.3%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.78
EPS Est.
-$0.52
EPS Surpr.
-50.0%
Revenue
—
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
-$0.50
EPS Est.
-$0.38
EPS Surpr.
-31.6%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.35
EPS Est.
-$0.36
EPS Surpr.
+2.8%
Revenue
—
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$0.41
EPS Est.
-$0.33
EPS Surpr.
-24.2%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.27
EPS Est.
-$0.29
EPS Surpr.
+6.9%
Revenue
—
Q3 FY2024
Aug 13, 2024Miss
EPS Actual
-$0.48
EPS Est.
-$0.30
EPS Surpr.
-60.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Q3 FY2027 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q2 FY2027 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q1 FY2027 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Q4 FY2026 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q3 FY2026 | $-0.49 | $-0.49 | $-0.49 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 5, 2026 | -6.3% | $17.76 | $17.55 | -1.18% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -50.0% | $11.53 | $11.34 | -1.65% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -31.6% | $9.03 | $9.09 | +0.66% |
| ▲ Q2 FY2025 | May 8, 2025 | +2.8% | $6.59 | $6.46 | -1.97% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -24.2% | $6.38 | $6.61 | +3.61% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +6.9% | $6.75 | $7.52 | +11.41% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -60.0% | $6.85 | $6.59 | -3.80% |
| ▲ Q2 FY2024 | May 8, 2024 | +9.1% | $9.55 | $9.61 | +0.63% |
Q1 FY2026-1.18%
Report Date
Mar 5, 2026
EPS Beat/Miss
-6.3%
Price Before
$17.76
Price After
$17.55
Q4 FY2025-1.65%
Report Date
Nov 6, 2025
EPS Beat/Miss
-50.0%
Price Before
$11.53
Price After
$11.34
Q3 FY2025+0.66%
Report Date
Jul 31, 2025
EPS Beat/Miss
-31.6%
Price Before
$9.03
Price After
$9.09
Q2 FY2025-1.97%
Report Date
May 8, 2025
EPS Beat/Miss
+2.8%
Price Before
$6.59
Price After
$6.46
Q1 FY2025+3.61%
Report Date
Mar 6, 2025
EPS Beat/Miss
-24.2%
Price Before
$6.38
Price After
$6.61
Q4 FY2024+11.41%
Report Date
Nov 7, 2024
EPS Beat/Miss
+6.9%
Price Before
$6.75
Price After
$7.52
Q3 FY2024-3.80%
Report Date
Aug 13, 2024
EPS Beat/Miss
-60.0%
Price Before
$6.85
Price After
$6.59
Q2 FY2024+0.63%
Report Date
May 8, 2024
EPS Beat/Miss
+9.1%
Price Before
$9.55
Price After
$9.61
Avg Beat Reaction+3.36%
Avg Miss Reaction-0.47%
Beat Rate3 / 8 quarters
Largest Move+11.41% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MNMD ends December
Mind Medicine (MindMed) Inc. (MNMD) most recently reported earnings on March 5, 2026 for Q1 FY2026, posting EPS of $-0.51 — missing the analyst consensus of $-0.48 by -6.3%. The next MNMD earnings date is expected around September 1, 2026.
Each quarter, investors track MNMD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MNMD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MNMD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MNMD earnings · 5 questionsMind Medicine (MindMed) Inc.'s next earnings report is expected around September 1, 2026. MNMD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MNMD historically reports after market close (AMC).
MNMD earnings datewhen is MNMD earningsMNMD next earnings datewhen does MNMD report earningsMNMD earnings calendar
▸ Source: FMP · Mind Medicine (MindMed) Inc. SEC filings · US GAAP · Mind Medicine (MindMed) Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026